Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or
unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy
(Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x...
Age: 18 - 99 years
Gender: All
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects
with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or
relapsed to standard of care (including pembrolizumab, if approved for that indicati...
Age: 18 years - 66+
Gender: All
Study of SRF388 in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Age: 18 years - 66+
Gender: All
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Age: 18 years - 66+
Gender: All
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how your body reacts
to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in
combination with cemiplimab.
The study has 2 parts. The goal of Part 1 (dose esca...
Age: 18 years - 66+
Gender: Male
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Age: 18 years - 66+
Gender: All
Study of Kidney Tumors in Younger Patients
This research trial studies kidney tumors in younger patients. Collecting and storing samples
of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may
help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) a...
Age: Birth - 29 years
Gender: All